TMEAD (Tuberculosis Monitoring Encouragement and Adherence Drive)

TMEAD (Tuberculosis Monitoring Encouragement and Adherence Drive) is an Initiative by Sensedose Technologies Pvt. Ltd. It offers a technology solution aimed at enhancing adherence to the Revised National TB Control Program (RNTCP) regimes, which helps in daily regime monitoring, avoiding interruptions in the treatment, reducing defaulters and analyzing patient data. Apart from helping patients to keep their daily regime in place, TMEAD eases work for Tuberculosis Health Visitors(TBHV) who needs to meet the challenge of tracking whether patient has taken the medicine or not.

Sensedose technologies is a healthcare startup that is working hand in hand with the public healthcare system to achieve the goal set by Hon. PM Narendra Modi, of eliminating TB by2025, and the global goal of Ending Tuberculosis by 2030. Sensedose platform brings complete TB ecosystem right from patient, caregivers, last-mile public healthcare executives and state TBofficers on a single platform. It facilitates real-time flow of vital patient care information and medication adherence data to all the stakeholder for taking an informed decision.

Sensedose is improving treatment outcomes for tuberculosis by ensuring, the patients follow their medication regimen and complete it in time. While the average adherence rate was 62%, which is inadequate compared to the target of 85% Adherence rate that is required to meet global goals of eliminating Tuberculosis, Sensedose has achieved an adherence rate of 92% after deploying their platform in Nashik.

For more information, please visit Link

Touched the lives of more than 250 patients. Nearly 27 patients have completed their medication regimen using the intervention and are now fully cured and living normal lives.

Using  IoT based solution, the existing adherence rate of 65% have grown to 98%